ATLANTA, Dec. 12, 2024
Xstrahl's XBeam has received FDA 510(k) Clearance for Use in the U.S. XBeam technology streamlines radiotherapy treatment planning and simplifies patient workflow for treating skin cancer, benign diseases, and palliative care. XBeam is the treatment planning software for superficial, orthovoltage, and electronic brachytherapy (eBt) treatments on all of Xstrahl's clinical systems. Used extensively throughout Europe, it is now approved for use in the U.S. XBeam streamlines treatment planning and simplifies patient workflow.
Advertisement
ATLANTA, Dec. 12, 2024 /PRNewswire-PRWeb/ -- Xstrahl, a global leader in the delivery of superficial and orthovoltage radiation therapy devices and preclinical radiation research systems, announced that Xstrahl's XBeam software has received U.S. Food and Drug Administration (FDA) 510(k) clearance. XBeam is the treatment planning software for superficial, orthovoltage, and electronic brachytherapy (eBt) treatments on all of Xstrahl's clinical systems. Used extensively throughout Europe, it is now approved for use in the U.S. XBeam streamlines treatment planning and simplifies patient workflow.
Advertisement
"We are pleased to announce that XBeam has received 510(k) Clearance for use in the U.S. and it will further streamline treatment planning with Xstrahl's superficial systems and Radiant™ Aura to bring radiation therapy to non-melanoma skin cancer (NMSC) patients in any dermatology office," said Adrian Treverton, CEO of Xstrahl. "XBeam is already used in Europe for superficial and orthovoltage treatments, and now our U.S. customers can calculate and run protocols for Radiant Aura using XBeam," he added.
With XBeam, you can calculate, protocol and export treatment plans for Xstrahl treatments with Radiant Aura and all other Xstrahl medical devices in the U.S. and worldwide. The calculations are based on machine-specific depth dose data and dose rate information. The intuitive user interface makes it easy to enter the physician's prescription and other patient-specific treatment parameters, for which XBeam then calculates the treatment exposure settings. The resulting protocol shows all relevant information for planning and treatment calculation and provides this to the system control, significantly simplifying the standard workflow.
Radiant Aura is the smallest, office-based radiation therapy device for dermatology practices available on the market today. It is the only system that delivers both eBt and superficial radiation therapy (SRT) to give dermatologists multiple treatment options for their NMSC patients.
For further information, please contact:
Kelly Withers
U.S. Divisional Sales Director - Dermatology
Tel: +1-602-509-4990, e-mail: [email protected]
Time zone: Pacific Time / USA
About Xstrahl
Xstrahl is a medical technology company that designs radiation delivery devices to support clinical teams and cancer researchers. For more than 25 years, Xstrahl has been shaping the development of superficial and orthovoltage radiation therapy and advancing preclinical radiation research. Xstrahl systems are in operation at more than 700 treatment and research facilities worldwide.
To learn more about Radiant Aura, visit www.radiant-therapy.com
To learn more about Xstrahl medical systems available in the U.S., please visit www.xstrahl.com
Media Contact
Kelly Withers, Xstrahl, 1 602-509-4990, [email protected], https://xstrahl.com/
Twitter, LinkedIn
View original content to download multimedia:https://www.prweb.com/releases/xbeam-from-xstrahl-receives-us-food-and-drug-administration-fda-510k-clearance-for-use-in-the-us-302330608.html
SOURCE Xstrahl
